Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nurix Therapeutics Inc (NRIX)

Nurix Therapeutics Inc (NRIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 667,962
  • Shares Outstanding, K 49,151
  • Annual Sales, $ 76,990 K
  • Annual Income, $ -143,950 K
  • 60-Month Beta 2.06
  • Price/Sales 9.22
  • Price/Cash Flow N/A
  • Price/Book 4.21
Trade NRIX with:

Options Overview Details

View History
  • Implied Volatility 120.22% ( +10.07%)
  • Historical Volatility 100.69%
  • IV Percentile 92%
  • IV Rank 60.28%
  • IV High 193.55% on 12/04/23
  • IV Low 8.94% on 03/19/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 211
  • Volume Avg (30-Day) 66
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 622
  • Open Int (30-Day) 1,156

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 05/31/24
See More
  • Average Estimate -0.72
  • Number of Estimates 6
  • High Estimate -0.47
  • Low Estimate -0.89
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.55 +8.21%
on 03/27/24
18.12 -25.06%
on 04/11/24
+0.16 (+1.19%)
since 03/22/24
3-Month
7.65 +77.52%
on 01/29/24
18.12 -25.06%
on 04/11/24
+5.62 (+70.60%)
since 01/22/24
52-Week
4.22 +221.80%
on 10/26/23
18.12 -25.06%
on 04/11/24
+2.78 (+25.74%)
since 04/21/23

Most Recent Stories

More News
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards? (Revised)

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

CTLT : 56.05 (+1.03%)
NRIX : 13.58 (-0.07%)
IKNA : 1.3000 (-2.26%)
SRZN : 9.25 (-1.65%)
Wall Street Analysts Predict a 233.33% Upside in Nurix Therapeutics, Inc. (NRIX): Here's What You Should Know

The mean of analysts' price targets for Nurix Therapeutics, Inc. (NRIX) points to a 233.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

NRIX : 13.58 (-0.07%)
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 16.67% and 20.91%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?...

NRIX : 13.58 (-0.07%)
BEAM : 24.10 (+0.84%)
Will Nurix Therapeutics, Inc. (NRIX) Report Negative Q1 Earnings? What You Should Know

Nurix Therapeutics, Inc. (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NRIX : 13.58 (-0.07%)
Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -15.79% and 45.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AFMD : 5.00 (-2.91%)
NRIX : 13.58 (-0.07%)
Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study

Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.

NVO : 125.26 (+2.08%)
GILD : 66.95 (+0.28%)
LGND : 68.53 (-5.44%)
NRIX : 13.58 (-0.07%)
Gilead (GILD) Exercises Option to License Nurix's Candidate

Gilead (GILD) exercises an option under its collaboration agreement with Nurix to license the latter???s investigational targeted protein degrader molecule NX 0479.

NVO : 125.26 (+2.08%)
GILD : 66.95 (+0.28%)
LGND : 68.53 (-5.44%)
NRIX : 13.58 (-0.07%)
Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead

Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.

GILD : 66.95 (+0.28%)
APTX : 0.0960 (+3.11%)
ANVS : 11.49 (+14.21%)
NRIX : 13.58 (-0.07%)
Strength Seen in Nurix Therapeutics, Inc. (NRIX): Can Its 5.7% Jump Turn into More Strength?

Nurix Therapeutics, Inc. (NRIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

NRIX : 13.58 (-0.07%)
PTGX : 26.61 (+3.90%)
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead...

GILD : 66.95 (+0.28%)
NRIX : 13.58 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics...

See More

Key Turning Points

3rd Resistance Point 14.82
2nd Resistance Point 14.46
1st Resistance Point 14.02
Last Price 13.58
1st Support Level 13.22
2nd Support Level 12.86
3rd Support Level 12.42

See More

52-Week High 18.12
Last Price 13.58
Fibonacci 61.8% 12.81
Fibonacci 50% 11.17
Fibonacci 38.2% 9.53
52-Week Low 4.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar